Brokerage firm Citigroup Maintains its rating on Catabasis Pharmaceuticals Inc(NASDAQ:CATB). In a research note issued to the investors, the brokerage major Lowers the price-target to $8.00 per share. The shares have been rated Buy. The rating by Citigroup was issued on Jun 9, 2016.
In a different note, On Mar 22, 2016, Citigroup said it Maintains its rating on Catabasis Pharmaceuticals Inc. In the research note, the firm Lowers the price-target to $21.00 per share. The shares have been rated ‘Buy’ by the firm.
Catabasis Pharmaceuticals Inc (CATB) shares turned negative on Wednesdays trading session with the shares closing down -0.12 points or -2.88% at a volume of 23,545. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.2. The peak price level was also seen at $4.2 while the days lowest was $4. Finally the shares closed at $4.05. The 52-week high of the shares is $16.96 while the 52-week low is $3.9. According to the latest information available, the market cap of the company is $62 M.
Catabasis Pharmaceuticals Inc(CATB) last announced its earnings results on May 12, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.61. Analysts had estimated an EPS of $-0.64.
Several Insider Transactions has been reported to the SEC. On Jun 30, 2015, Jean George (director) purchased 258,776 shares at $12.00 per share price.Also, On Jun 30, 2015, Nicholas Galakatos (director 10% owner) purchased 376,695 shares at $12.00 per share price.On Jun 30, 2015, Ventures, Inc. Medimmune (10% owner) purchased 223,439 shares at $12.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Catabasis Pharmaceuticals Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules or bioactives each with known pharmacological activity joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Company’s product development pipeline includes three clinical-stage product candidates namely CAT-1004 CAT-2000 series including CAT-2054 and CAT-2003 and CAT-4001 and various programs in preclinical development.